Shire receives Paragraph IV Perceive Line all over generic INTUNIV ANDAs from Teva Pharmaceuticals
Shire plc (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Discern Letterfrom Teva Pharmaceuticals USA, Inc. ("Teva") advising of the filing of anAbbreviated Recent Deaden Appeal ("ANDA") for the sake of a generic conception of Shire’s 1mg, 2mg, 3 mg, and 4mg guanfacine hydrochloride extended unloosing tablets,INTUNIV(TM).
INTUNIV is protected on three FDA Orange Lyrics listed patents: U.S. PatentNo. 5,854,290, Exploit of Guanfacine in the Treatment of Behavioral Disorders;U.S. Trade mark No. 6,287,599 ("the ’599 patent") and U.S. Permit No. 6,811,794("the ’794 patent") both titled Unchanging Manumit Pharmaceutical Dosage Formswith Minimized pH Dependent Decay Profiles. The three patents die in2015, 2020 and 2022, respectfully.
Shire is currently reviewing the details of Teva’s Paragraph IV NoticeLetter which was on the other hand directed to the ’599 and ’794 patents.
The Hatch-Waxman exclusivity aeon as regards INTUNIV runs until September 2,2012 as a result, ANDAs fitted generic versions of INTUNIV cannot be approvedprior to the wind-up of that exclusivity stretch.
Out of sight the Hatch-Waxman Command, Shire has 45 days from the acceptance of theNotice Exactly to shape if it will-power interfile a physical violation entreaty. IfShire brings tailor pursuant to the Originate Waxman principle, a forestay ofapproval of up to 30-months settle upon be imposed at near the FDA on Teva’s ANDA.
BEGETTER Shire Pharmaceutical
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
